Back

Non-vitamin K antagonist oral anticoagulants versus warfarin and the risk of cataract in patients with atrial fibrillation: A real-world cohort study

29 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Risk and benefits of antithrombotic drugs Anticoagulants ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Shu-Man Lin

Tzu Chi General Hospital, Hualien (Taiwan)

5 More presentations in this session

Presentation thumbnail
External validation of novel bleeding risk scores, ARC-HBR and PRECISE-HBR, in 5116 consecutive ACS patients in clinical practice
Professor A. Khand (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Prognostic impact of post-procedural low-molecular-weight heparin in high-bleeding risk patients undergoing pci for acute myocardial infarction
Doctor S. Qin (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Impact of recurrent venous thromboembolism and major bleeding events on subsequent mortality in patients with and without active cancer: Insights from the COMMAND VTE Registry-2
Doctor S. Kobayashi (Tsu, JP)
Abstract Slides
Presentation thumbnail
Single versus dual antiplatelet therapy after transcatheter aortic valve implantation in patients without an indication for anticoagulation: a systematic review and meta-analysis
Doctor C. Sanchez Serrano (Ciudad De Mexico, MX)
Abstract Slides
Presentation thumbnail
Concomitant antiplatelet therapy in anticoagulated TAVI patients with atrial fibrillation: impact of sex on bleeding and ischaemic events in ENVISAGE-TAVI AF
Doctor G. Dangas (New York, US)
Abstract Slides

Access the full session

Session thumbnail
Risk and benefits of antithrombotic drugs

The Event

Event poster

ESC Congress 2026

29 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk of dementia in patients treated with non-vitamin k antagonist oral anticoagulant or warfarin for nonvalvular atrial fibrillation
31 August 2019
thumbnail
Congress Presentation
Comparative characteristics of anticoagulants used in cancer-associated thrombosis
20 June 2025
thumbnail
Webinar
Are NOACs already outdated? New trends in anticoagulation therapy
12 December 2022
thumbnail
Congress Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources